secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-05-15T23:55:16+00:00
Accession:  0001104659-26-062865
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics Q2 FY2026 net loss narrows to $4.5M; FDA decision on ONS-5010 expected May 2026
--------------------------------------------------------------------------------

- Net loss of $4.5M ($0.05/sh) vs $46.4M ($1.50/sh) YoY; adjusted net loss $14.1M ($0.16/sh).
- LYTENAVA unit sales in Europe down ~10% QoQ; cost reduction steps initiated to improve margins.
- Cash $7.7M as of Mar 31; raised ~$4M in March offering and $4.2M net in April registered direct offering.
- FDA formal dispute resolution meeting completed in April; written decision expected within May 2026.
- Entered Swiss distribution agreement with Mediconsult AG; targeting 2027 launch pending marketing authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/0001104659-26-062865-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926062865/tm2614868d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-062865

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer